Search company, investor...

Founded Year

2016

Stage

Take Private | Alive

About Xynomic Pharma

Xynomic Pharma is a biopharmaceutical company. It focuses on in-licensing, developing, and commercializing oncology drug candidates. The company was founded in 2016 and is based in Poway, California.

Headquarters Location

13029 Danielson Street Suite 120

Poway, California, 92064,

United States

Loading...

Loading...

Xynomic Pharma Patents

Xynomic Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • experimental cancer drugs
  • fluoroarenes
  • monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/11/2022

9/12/2023

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Protein kinase inhibitors, Fluoroarenes

Grant

Application Date

3/11/2022

Grant Date

9/12/2023

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Protein kinase inhibitors, Fluoroarenes

Status

Grant

Latest Xynomic Pharma News

Oligodendroglioma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Xynomic Pharma, Oblato, Incyte Crp, SpringWorks Therapeutics

Jan 12, 2024

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Oligodendroglioma pipeline constitutes 10+ key companies continuously working towards developing 10+ Oligodendroglioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Oligodendroglioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “ Oligodendroglioma Pipeline Insight, 2023 “ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oligodendroglioma Market. Some of the key takeaways from the Oligodendroglioma Pipeline Report: Companies across the globe are diligently working toward developing novel Oligodendroglioma treatment therapies with a considerable amount of success over the years. Oligodendroglioma companies working in the treatment market are Xynomic Pharmaceuticals, Inc., Oblato, Inc., SpringWorks Therapeutics, Incyte Corporation, and others, are developing therapies for the Oligodendroglioma treatment Emerging Oligodendroglioma therapies in the different phases of clinical trials are- PCI-24781, OKN-007, Mirdametinib, Pemigatinib, Retifanlimab, and others are expected to have a significant impact on the Oligodendroglioma market in the coming years. In January 2024, AbbVie is currently advancing the clinical development of BBV-706, with the drug currently in Phase I trials targeting Oligodendroglioma. GlobalData notes that there is insufficient historical data for Phase I drugs addressing Oligodendroglioma to establish a benchmark PTSR (Patient and Treatment Satisfaction Rate) for this specific phase. Oligodendroglioma Overview Oligodendroglioma (OG) originates from oligodendrocytes, glial cells responsible for producing myelin—a fatty white substance that covers nerves, facilitating faster transmission of signals (impulses). Typically, oligodendrogliomas are located in the frontal lobe of the cerebrum. PCI-24781: Xynomic Pharmaceuticals, Inc. Further Oligodendroglioma product details are provided in the report. Download the Oligodendroglioma pipeline report to learn more about the emerging Oligodendroglioma therapies Some of the key companies in the Oligodendroglioma Therapeutics Market include: Key companies developing therapies for Oligodendroglioma are – AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cavion LLC, Celldex Therapeutics Inc, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, Immatics Biotechnologies GmbH, Ipsen SA, Leadiant Biosciences Inc, Millennium Pharmaceuticals Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc, and others. The Oligodendroglioma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Oligodendroglioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oligodendroglioma Treatment. Oligodendroglioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Oligodendroglioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oligodendroglioma market. The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Oligodendroglioma Pipeline Market Drivers Rising incidence of the Oligodendroglioma, advancements in pharmacology and molecular biology to promote drug development are some of the important factors that are fueling the Oligodendroglioma Market. Oligodendroglioma Pipeline Market Barriers However, high cost associated with the management, side effects associated with the treatment and other factors are creating obstacles in the Oligodendroglioma Market growth.

Xynomic Pharma Frequently Asked Questions (FAQ)

  • When was Xynomic Pharma founded?

    Xynomic Pharma was founded in 2016.

  • Where is Xynomic Pharma's headquarters?

    Xynomic Pharma's headquarters is located at 13029 Danielson Street, Poway.

  • What is Xynomic Pharma's latest funding round?

    Xynomic Pharma's latest funding round is Take Private.

  • Who are the investors of Xynomic Pharma?

    Investors of Xynomic Pharma include Xu-Nuo Pharma, Bison Capital Acquisition, Tinglin Mark Xu, Northern Light Venture Capital, Hakim Co. and 5 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.